About Mirna Therapeutics
Mirna is a biopharmaceutical company focused on development of a pipeline of microRNA-based oncology therapeutics.
Mirna’s lead product candidate, MRX34, the first microRNA mimic to enter clinical development in oncology, was studied as a single agent in a multicenter Phase 1 clinical trial, which included patients with primary liver cancer, other solid cancers, and hematological malignancies (lymphomas and leukemias). MRX34 was designed to deliver a mimic of the naturally occurring microRNA tumor suppressor miR-34, which is underexpressed in a wide variety of cancers. MRX34 entered clinical testing in 2013. In September 2016, Mirna voluntarily halted enrollment and dosing in the clinical study following multiple immune-related severe adverse events (SAEs) observed in patients dosed with MRX34 over the course of the trial.
Mirna’s owned and in-licensed intellectual property portfolio includes at least 10 issued U.S. patents and more than 42 pending U.S. and foreign applications.
Mirna Therapeutics was founded in 2007 and is located in Austin, Texas.